Hopes that Novartis deal on tuberculosis will spur donations for HIV and malariaBMJ 2004; 328 doi: https://doi.org/10.1136/bmj.328.7431.70-a (Published 09 January 2004) Cite this as: BMJ 2004;328:70
- Fiona Fleck
A pledge last month by Swiss pharmaceuticals giant Novartis to donate $7m(£3.9m; €5.5m) worth of drugs to 500 000 patients with tuberculosis in poor countries over the next five years has raised hopes that other drug companies will follow suit to fight HIV/AIDS and malaria.
Under an agreement with the World Health Organization on 19 December, Novartis will provide drugs to help poor countries obtain and distribute drugs to patients with tuberculosis. Two million people die of the disease every year, many of whom have HIV infection or AIDS. There are signs that …
Log in using your username and password
Log in through your institution
Register for a free trial to thebmj.com to receive unlimited access to all content on thebmj.com for 14 days.
Sign up for a free trial